Pharmaceuticals South Korea

South Korea Regenerative Medicine Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

South Korea Regenerative Medicine Market Industry Trends and Forecast to 2034: Segmented by (Product, Application, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

South Korea · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $768.4 Mn Placeholder estimate
Estimate 2025 $906.7 Mn 1.7% of the global market
Projected 2034 $4.02 Bn 343.5% Adds $3.12 Bn over 9 forecast years
CAGR 2025–2034 18.0% Faster than 100% of 5 Pharmaceuticals markets here
Key players 6 +1
  • South Korea is 1.74% of the global market.
  • In APAC, the largest is China at $4.87 Bn.
  • Fastest growing: India at 19.8% a year.
  • South Korea ranks 4th of 14 by size in APAC.

Market size projection

South Korea

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$3.12 Bn total, 2026–2034

Year-by-year market size, 2024–2034
Regenerative Medicine Market market size by year, South Korea
YearMarket sizeChange that yearSince 2025
2024 (estimate) $768.4 Mn — —
2025 (base) $906.7 Mn +$138.3 Mn —
2026 (forecast) $1.07 Bn +$163.2 Mn +18%
2027 (forecast) $1.26 Bn +$192.6 Mn +39.2%
2028 (forecast) $1.49 Bn +$227.3 Mn +64.3%
2029 (forecast) $1.76 Bn +$268.2 Mn +93.9%
2030 (forecast) $2.07 Bn +$316.4 Mn +128.8%
2031 (forecast) $2.45 Bn +$373.4 Mn +170%
2032 (forecast) $2.89 Bn +$440.6 Mn +218.5%
2033 (forecast) $3.41 Bn +$519.9 Mn +275.9%
2034 (forecast) $4.02 Bn +$613.5 Mn +343.5%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

South Korea Regenerative Medicine Market Analysis at a glance
Market size, 2025$906.7 Mn placeholder estimate
Forecast, 2034$4.02 Bn placeholder estimate
Growth (CAGR), 2025–203418.0% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsProduct, application and end user (see all)
Key playersGilead Sciences, Inc., Novartis AG, Vertex Pharmaceuticals, Smith & Nephew, Organogenesis and 1 more (see all)
Regulator in South KoreaMFDSSource: Ministry of Food and Drug Safety. Checked 19 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The South Korea Regenerative Medicine Market Analysis Executive Summary

Regenerative medicine aims to repair or replace damaged cells, tissues and organs using stem cells, gene therapy and engineered tissue.

Key segments of the regenerative medicine market include product (Cell Therapies, Gene Therapies and Tissue-Engineered Products) and application (Orthopedics, Cardiovascular and Dermatology).

Bar chart: South Korea Regenerative Medicine market size, 2024–2034, placeholder estimates. $768.4 Mn in 2024, $906.7 Mn in 2025 and $4.02 Bn in 2034, 18.0% CAGR.
South Korea Regenerative Medicine market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

South Korea Regenerative Medicine Market Dynamics

Market Growth Drivers

Ageing populations, more chronic disease, broader access to medicines and steady new drug approvals are driving the regenerative medicine market.

Opportunity

Personalized treatments, local manufacturing and new technologies for making medicines give the regenerative medicine market room to grow.

Market Restraints

Price controls, long and costly development, patent expiries and strict quality rules hold back the regenerative medicine market.

Competitive Landscape for Regenerative Medicine Market in South Korea

The regenerative medicine market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Regenerative Medicine Market in South Korea

Regenerative Medicine in South Korea: rules and payment

The Ministry of Food and Drug Safety (MFDS) approves medicines before they can be sold.⁠[1] Everyone is covered by National Health Insurance; the Health Insurance Review and Assessment Service (HIRA) reviews claims and what is covered.⁠[2]

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for regenerative medicine. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in South Korea.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Regenerative Medicine right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 22 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Regenerative Medicine in context

South Korea compared

  • Health spending per person: 3,137 US$ per person (2024). World: 1,317 US$ per person (2023). 5th highest of the 17 countries we cover in APAC.[1]
  • Doctors: 2.61 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 6th highest of the 17 countries we cover in APAC.[2]
  • People aged 65 and over: 20.3% of people (2025). World: 10.4% of people (2025). 3rd highest of the 18 countries we cover in APAC.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 22 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 21 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 22 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Regenerative Medicine market in South Korea?
Placeholder estimate: about $906.7 Mn in 2025, rising to about $4.02 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Regenerative Medicine market in South Korea growing?
Placeholder estimate: about 18.0% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Regenerative Medicine market report cover?
The report splits the market by product (Cell Therapies, Gene Therapies, Tissue-Engineered Products, Biomaterials), application (Orthopedics, Cardiovascular, Dermatology, Oncology and more) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Regenerative Medicine market?
Key players include Gilead Sciences, Inc., Novartis AG, Vertex Pharmaceuticals, Smith & Nephew, Organogenesis and Integra Life Sciences Corporation.
What is driving the Regenerative Medicine market?
Ageing populations, more chronic disease, broader access to medicines and steady new drug approvals are driving the regenerative medicine market.
Who regulates Regenerative Medicine in South Korea?
The Ministry of Food and Drug Safety (MFDS) approves medicines before they can be sold. Source: Ministry of Food and Drug Safety. Checked 19 Nov 2026.
How is healthcare paid for in South Korea?
Everyone is covered by National Health Insurance; the Health Insurance Review and Assessment Service (HIRA) reviews claims and what is covered. Source: Health Insurance Review and Assessment Service (HIRA). Checked 19 Nov 2026.
How much research is published on Regenerative Medicine?
PubMed lists 16,207 papers on Regenerative Medicine added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 22 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in South Korea

See all

Related on cell and gene therapy and bones and joints

See the topic